Press Releases XOMA Royalty Corporation Nasdaq

Equities

XOMAO

US98419J4040

Market Closed - Nasdaq Other stock markets 16:30:01 2024-07-16 EDT			5-day change	1st Jan Change
24.92 ^USD	-0.91%		-0.48%	-0.80%

07-10	XOMA Corporation will Change its Name to XOMA Royalty Corporation	CI
07-09	Xoma Changes Name to Xoma Royalty	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

XOMA Declares Quarterly Preferred Stock Dividends	06-20	AQ
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher	06-13	AQ
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	06-12	AQ
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	05-14	AQ
Xoma: Q1 Earnings Snapshot	05-09	AQ
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	05-09	AQ
XOMA : 2024 Letter to Shareholders	05-09	PU
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	04-30	AQ
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	04-25	AQ
XOMA : Acquisition/Asset Disposal - Form 8-K	04-03	PU
XOMA Corporation Announces Closing of Tender Offer	04-03	AQ
XOMA Declares Quarterly Preferred Stock Dividends	03-21	AQ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	03-19	AQ
Xoma: Q4 Earnings Snapshot	03-08	AQ
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	03-08	AQ
XOMA to Present at Upcoming Investor Conferences in March	02-28	AQ
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	02-19	AQ
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	02-16	PR
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	02-16	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	01-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases XOMA Royalty Corporation Nasdaq

Equities

XOMAO

US98419J4040

Press Releases

Filters